Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.41 USD
Change Today 0.00 / 0.00%
Volume 293.8K
RXII On Other Exchanges
Symbol
Exchange
Frankfurt
NASDAQ CM
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$0.41
Previous Close
$0.41
Day High
$0.43
Day Low
$0.41
52 Week High
09/3/14 - $3.98
52 Week Low
05/28/15 - $0.34
Market Cap
23.5M
Average Volume 10 Days
664.4K
EPS TTM
$-0.67
Shares Outstanding
57.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma. The company’s preclinical program includes the development of products for ocular indications with RXI-109, including retinal and corneal scarring. Its discovery stage development programs include a dermatology franchise for the discovery of collagenase and tyrosinase targets for its RNAi platform; and ophthalmology franchise, a program for the discovery of sd-rxRNA compounds for oncology indications, including retinoblastoma. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

15 Employees
Last Reported Date: 05/22/15
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $495.3K
Chief Development Officer
Total Annual Compensation: $413.6K
Compensation as of Fiscal Year 2014.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation Receives Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye

RXi Pharmaceuticals Corporation announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its novel, self-delivering RNAi platform. The patent, titled "RNA Interference in Ocular Indications," covers methods of use of RXi's VEGF-targeting and CTGF-targeting self-delivering rxRNAs®, including RXI-109, for use in the eye. The patent, once issued, will be scheduled to expire in 2031. This core patent, within RXi's intellectual property portfolio, broadens the coverage of RXi's self-delivering platform and provides coverage of RXI-109 for the treatment of ocular fibrosis. Scarring of the eye, as a consequence of disease or injury, can result in impairment or loss of vision. Medical or surgical treatments for the scarring component of ocular indications is limited. A therapeutic, such as RXI 109, that is effective in reducing the activity of CTGF could have great benefit for patients whose ocular condition has an active scarring component. To date, there are no FDA-approved therapeutics for the treatment and prevention of scarring in the eye.

RXi Pharmaceuticals Seeks Acquisitions

RXi Pharmaceuticals Corporation (NasdaqCM:RXII) is looking for acquisitions. The company has announced a Composite Units Offering. The company said it may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies or to fund the development of any such complementary businesses, products or technologies that it may acquire in a stock-based acquisition, although it says it has no current plans for any such acquisitions.

RXi Pharmaceuticals Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 11:30 AM

RXi Pharmaceuticals Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 11:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Geert Cauwenbergh, Chief Executive Officer, President, Director and Member of Corporate Governance Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $0.41 USD 0.00

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 128.2x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 181.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.